e-learning
resources
Milan 2017
Wednesday, 13.09.2017
New perspectives from experimental models of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension
X. Sun (Amsterdam, Netherlands)
Source:
International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Session:
New perspectives from experimental models of pulmonary hypertension
Session type:
Oral Presentation
Number:
4660
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
X. Sun (Amsterdam, Netherlands). The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension. 4660
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Assessment of simvastatin treatment on pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 408-417
Year: 2016
Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
The role of combination therapy in managing pulmonary arterial hypertension
Source: Eur Respir Rev 2014; 23: 469-475
Year: 2014
Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Initial dual oral combination therapy in pulmonary arterial hypertension
Source: Eur Respir J 2016; 47:1727-1736
Year: 2016
Combined treatment in pulmonary hypertension
Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine
Year: 2016
Haemodynamic effects of exercise therapy in stable, optimally treated pulmonary arterial hypertension
Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Year: 2017
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept